Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19NO |
Molecular Weight | 265.3496 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC\C=C1\C2=CC=CC=C2OCC3=C1C=CC=C3
InChI
InChIKey=HVKCEFHNSNZIHO-MHWRWJLKSA-N
InChI=1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10+
Molecular Formula | C18H19NO |
Molecular Weight | 265.3496 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11037801
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11037801
Z-N-desmethyldoxepin is an active metabolite of doxepin, a tricyclic antidepressant. Z-N-desmethyldoxepin appeared to be a terminal oxidative metabolite, in comparison with isomeric form E-N-desmethyl-doxepin, which is undergone further oxidation under the action of CYP2D6 activity.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1981729
Curator's Comment: College of Pharmacy, University of Saskatchewan
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Geometric isomerization of doxepin during its N-demethylation in humans. | 1991 May-Jun |
|
Determination of doxepin and desmethyldoxepin in human plasma using liquid chromatography-tandem mass spectrometry. | 2000 May 26 |
|
Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. | 2000 Oct |
|
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. | 2002 Oct |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11037801
In 'metabolic consumption' experiments with liver microsomes (having measurable CYP2D6 activity) and initial substrate concentration of 1 microM, the consumption of E-doxepin was greater than that of Z-doxepin. With N-desmethyldoxepin, quinidine inhibited the consumption of E-N-desmethyl-doxepin whereas Z-N-desmethyldoxepin appeared to be a terminal oxidative metabolite. CYP2D6 is a major oxidative enzyme in doxepin metabolism; predominantly catalysing hydroxylation with an exclusive preference for the E-isomers. The relatively more rapid metabolism of E-isomeric forms, and the limited metabolic pathways for the Z-isomers explained the apparent enrichment of Z-N-desmethyldoxepin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:17:36 UTC 2023
by
admin
on
Fri Dec 15 18:17:36 UTC 2023
|
Record UNII |
J7JTC0A5D6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6433351
Created by
admin on Fri Dec 15 18:17:37 UTC 2023 , Edited by admin on Fri Dec 15 18:17:37 UTC 2023
|
PRIMARY | |||
|
J7JTC0A5D6
Created by
admin on Fri Dec 15 18:17:37 UTC 2023 , Edited by admin on Fri Dec 15 18:17:37 UTC 2023
|
PRIMARY | |||
|
DTXSID60217319
Created by
admin on Fri Dec 15 18:17:37 UTC 2023 , Edited by admin on Fri Dec 15 18:17:37 UTC 2023
|
PRIMARY | |||
|
67035-76-1
Created by
admin on Fri Dec 15 18:17:37 UTC 2023 , Edited by admin on Fri Dec 15 18:17:37 UTC 2023
|
PRIMARY | |||
|
142340
Created by
admin on Fri Dec 15 18:17:37 UTC 2023 , Edited by admin on Fri Dec 15 18:17:37 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|